Integrins involved in the adhesion of megakaryocytes to fibronectin and fibrinogen.
We studied integrins involved in the adhesion of resting and activated megakaryocytes (MK) to fibronectin (FN) and fibrinogen (FGN). Guinea pig MK were isolated and in some experiments were activated by thrombin. MK adhering to FN or FGN coated on coverslips were quantitated by a computerized image analysis program. The binding of soluble human FN to MK was detected by Western blotting. Anti-integrin antibodies, disintegrins, and cyclic RGD peptides were used to identify integrins involved in the adhesion of MK to FN or FGN. Resting MK adhered to coverslips with immobilized FN. The adhesion of MK to FN was primarily inhibited by an anti-alpha5 antibody and EMF-10, a distintegrin highly specific for alpha5 beta1. However, the adhesion of MK to FN was not blocked by agents that inhibit alphaIIb beta3, alphav beta3 or alpha4 beta1. A beta1 activating antibody increased the number of MK bound to FN due to the activation of alpha5 beta1. The binding of soluble FN was also primarily inhibited by agents that block alpha5 beta1. Resting MK did not adhere to FGN. However, MK activated by thrombin did adhere to FGN. This binding was mediated by alphaIIb beta3, because binding was inhibited by bitistatin, a disintegrin, and a cyclic RGD peptide that are known to block this integrin. The binding of thrombin-activated MK to FN was mediated by both alpha5 beta1 and alphaIIb beta3 based on the additive effect of agents that inhibit these integrins. The study indicates that resting MK bind to FN but not to FGN and that alpha5 beta1 is the major integrin involved in the binding of MK to FN. Activated MK bind to FGN primarily by alphaIIb beta3. However, the binding of activated MK to FN is due to both alpha5 beta1 and alphaIIb beta3. The demonstration that alpha5 beta1 and that alphaIIb beta3 are involved in MK adhesion indicates that these integrins may have a role in MK maturation and platelet production.
Cardeza Foundation for Hematologic Research, the Department of Medicine, Biochemistry and Molecular Pharmacology, Thomas Jefferson Medical College, Philadelphia, PA, USA.
P K
PK
Schick
C M
CM
Wojenski
X
X
He
J
J
Walker
C
C
Marcinkiewicz
S
S
Niewiarowski
D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D019483:Disintegrins / Q000494:pharmacology*; D004492:Edetic Acid / Q000494:pharmacology; D005340:Fibrinogen / Q000378:metabolism*; D005353:Fibronectins / Q000378:metabolism*; D006168:Guinea Pigs; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008533:Megakaryocytes / Q000166:cytology* / Q000187:drug effects; D010455:Peptides / Q000494:pharmacology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors / Q000502:physiology*; D017469:Receptors, Fibronectin / Q000037:antagonists & inhibitors / Q000502:physiology*; D012910:Snake Venoms; D013917:Thrombin / Q000494:pharmacology; D019010:Vascular Cell Adhesion Molecule-1 / Q000378:metabolism; D014757:Viper Venoms / Q000494:pharmacology; D019096:Vitronectin / Q000378:metabolism
D019483:Disintegrins; D005353:Fibronectins; D010455:Peptides; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D017469:Receptors, Fibronectin; D012910:Snake Venoms; D019010:Vascular Cell Adhesion Molecule-1; D014757:Viper Venoms; D019096:Vitronectin; C062186:bitistatin; D005340:Fibrinogen; D004492:Edetic Acid; D013917:Thrombin